Med. praxi. 2014;11(4):159-163 [Interní Med. 2014; 16(3): 93-97]

Pharmacotherapy of chronic venous disorder

MUDr.Lukáš Hnátek, Ph.D.
Angicor, s. r. o., Zlín

Chronic venous disorder (CVD) is a common illness with high incidence existing especially in Europe and North America. The main goal

of Venoactive Drugs (VAD) is to eliminate the symptoms of CVD (venous pain, fatigue, etc.). But there are some VAD that could be used

also for treatment of venous oedema and venous ulcer. There are many papers that prove their effectiveness in the experiment and in

the microcirculation. The most effective substance is micronized purified flavonoid fraction (MPFF) of diosmin hesperidin. It is proved

that this substance could be used as an effective supplementary treatment of symptoms after venous intervention. Only MPFF diosmin

hesperidin received the best recommendation – 1B in the last guidelines for VAD therapy.

Keywords: chronic venous disorder, venoactive drugs, micronized purified flavonoid fraction of diosmin hesperidin

Published: June 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hnátek L. Pharmacotherapy of chronic venous disorder. Med. praxi. 2014;11(4):159-163.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Beebe-Dimmer JL, Pfeifer J, Engel JS, Schottenfeld D. The epidemiology of chronic venous insufficiency and varicose veins. Annals of Epidemiology. 2005; 15: 175-184. Go to original source... Go to PubMed...
    2. Vojtíšková, J. Czech Vein Program - výsledky epidemiologického programu. Praktická flebologie. 2012; 21: 8-13.
    3. Weindorf N, Schultz-Ehrenburg U. The development of varicose veins in children and adolescents (in German). Phleboligie. 1990; 43: 573-577.
    4. Markel A, Manzo RA. Bergelin RO., Strandness DE. Valvular reflux after deep vein thrombosis: Incidence ant time of occurence. Journal of Vascular Surgery. 1992; 15: 377-384. Go to original source...
    5. Danielsson G, Arfvidsson B, Ëklof B, et al. Reflux from thigh to calf, the major pathologyin chronic venous ulcer disease: surgery indicated in the majority of patients. Vascular and Endovascular Surgery. 2004; 38: 209-219. Go to original source... Go to PubMed...
    6. Ramelet AA, Boisseaub MR, Allegra C, Nicolaides A, Jaeger K, Carpentier P, Cappelli R, Forconi S. Veno-active drugs in the management of chronic venous disease. An international consensus statement: Current medical position, prospective views and final resolution. Clinical Hemorheology and Microcirculation. 2005; 33: 309-319. Go to PubMed...
    7. Rabe E, Guex JJ, Morrison N, Ramelet AA, Schuller-Petrovic S, Scuderi A, Staelens I, Pannier F. Treatment of chronic venous disease with flavonoids: recommendations for treatment and further studies. Phlebology. 2013 Sept., 28 (6): 308-319. Go to original source... Go to PubMed...
    8. Rabe E, Jaeger KA, Bulitta M, Pannier F. Calcium dobesilate in patients suffering from chronic venous insufficiency: a double-blind, placebo-controlled, clinical trial. 2011 Jun; 26 (4): 162-168, Phlebology. Go to original source... Go to PubMed...
    9. Navrátilová, Z. Efficacy of a 6-month treatment with Detralex in Patients with venous edema. Phlebolymphology. 2010; 17(3): 137-143.
    10. Akbulut, B. Calcium dobesilate and oxerutin: effectiveness of combination therapy. 2010 Apr; 25 (2): 66-71, Phlebology.
    11. Allaert, FA. Meta-analysis of the impact of the principal venoactive drugs agents on malleolar venous edema. 2012 Aug.; 31(4): 310-315.
    12. Lenkovic M, Zgombic ZS, Blazic TM, Brajac I, Perisa D. Benefit of Daflon 500 mg in the reduction of chronic venous disease-related symptoms. Phlebolymphology. 2012; 19(2): 79-83.
    13. Takase S, et al. Venous hypertension, inflammation and valve remodeling. European Journal of Vascular and Endovascular Surg. 2004 Nov; 28(5): 484-493. Go to original source... Go to PubMed...
    14. Iriz E, Vural C, Ereren E, Poyraz A, Erer D, Oktar L, Gokgoz L, Halit V, Soncul H. Effects of calcium dobesilate and diosmin-hesperidin on apoptosis of venous wall in primary varicose veins. 2008 Aug; 37(3): 233-240, Vasa. Go to original source... Go to PubMed...
    15. Alda O, Valero MS, Pereboom D, Serrano P, Azcona JM, Garay RP. In vitro effect of calcium dobesilate on oxidative/ inflammatory stress in human varicose veins. 2011 Dec; 26(8): 332-337, Phlebology.
    16. Nicolaides, AN. From symptomps to leg edema: efficacy of Daflon 500 mg. Angiology. 2003 Jul-Aug; 54(Suppl 1): S33-44. Go to original source... Go to PubMed...
    17. Coleridge-Smith P, Lok C, Ramelet AA. Venous leg ulcer: a meta-analysis of adjuctive therapy with micronized purified flavonoid fraction. European Journal of Vascular and Endovasular Surg. 2005 Aug.; 30(2): 198-208. Go to original source... Go to PubMed...
    18. Roztočil K, Štvrtinová V, Strejček J. Efficacy of 6-month treatment with Daflon 500mg in patients with venous leg ulcers associated with chronic venous insufficiency. International Angiology. 2003; 22(1): 1-8.
    19. Pokrovsky AV, VS Saveljev, Kirienko AI, et al. Stripping of the great saphenous vein under micronized purified flavonoid fraction (MPFF) protection (results of the Russian multicenter controlled trial DEFANCE). 2008; 15: 45-51, Phlebolymphology.
    20. Veverkova L, Jedlicka V, Wechsler J, Kalac J. Analysis of the various procedures used in great saphenous vein surgery in the Czech Republic and benefit of Daflon 500 mg to postoperative symptoms. Phlebolymphology. 2006; 13(4): 181-220.
    21. Pitsch F. Benefit of Daflon 500 mg in combination with sclerotherapy of teleangiectasias of the lower limbs: results form the SYNERGY and SATISFY surveys. 2011; 19(4): 182-187, Phlebolymphology.
    22. Bogachev VY, Golovanova OV, Kuznetsov AN, Shoekyan AO, et al. Can Micronized Purified Flavonoid Fraction (MPFF) improve outcomes of lower ertremity varicose vein endovenous treatment? First results from DECISION study. 2013; 20(4): 181-187, Phlebolypmphology.
    23. Crébassa V, Karihuel J. Micronized Purified Flavonoid Fraction Treatment Improves Cutanous Outcomes and Patient's Satisfaction with Slerotherapy for Superficial Varicosities. 2013; 32(5) Suppl. 1: 105, International Angiology.
    24. Perrin M, Ramelet AA. Pharmacological treatment of primary chronic venous disease: rationale, results and unanswered questions. 2011 Jan; 41(1): 117-125, European Journal of Vascular and Endovascular Surgery. Go to original source... Go to PubMed...
    25. Perrin M, Nicolaides A. The Updates International Guidelines on The Management of Chronic Venous Disorders of the Lower Limbs and the Place of Venoactive Drugs. Int. Angiol. 2013; 32(suppl. 1): 106-107.
    26. The Essentials from the XVIIth World Meeting of the Union Internationale de Phlébologie. Boston, USA: September 2013; 20(3): 138-144, Phlebolymphology.
    27. Gloviczki, P. Handbook of Venous Disorders. London : Hodder Arnold, 2009.

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.